THE 30-SECOND OVERVIEW
At a glance
Kisspeptin-10 and kisspeptin-54 are not two different compounds so much as two lengths of the same one, and that makes them an unusually clean case study in how peptide fragments relate to their parent. Both come from a single gene, both act on a single receptor, and the differences that matter, principally half-life, follow directly from the length difference. The human research record, which is stronger than for most peptides in this catalogue, splits between them in an instructive way.
One gene, several fragments
The KISS1 gene encodes a 145-amino-acid precursor protein. Processing enzymes cut it down to kisspeptin-54, a 54-residue peptide originally named metastin because it was first characterised in 2001, by Kotani and colleagues among others, as a metastasis-suppressing factor. Further cleavage produces shorter fragments: kisspeptin-14, kisspeptin-13 and kisspeptin-10.
The structural fact that decides everything else is that all of these fragments share the same C-terminal ten amino acids, and that decapeptide is the part the receptor recognises. Kisspeptin-10 is that shared active core, the shortest fully active fragment. Every kisspeptin binds and activates the same receptor, KISS1R, formerly known as GPR54, with broadly similar potency in vitro.
Physiologically, kisspeptin signalling sits at the very top of the reproductive axis. Kisspeptin neurons in the hypothalamus drive gonadotropin-releasing hormone secretion, which drives luteinising hormone and follicle-stimulating hormone from the pituitary, which drive the gonads. Inactivating mutations in KISS1R cause failure of puberty, which is the human genetics that made this system famous.
The practical difference is half-life
If the fragments are equivalent at the receptor, what separates them in use is what happens in circulation. Kisspeptin-10, at ten residues, is cleared very quickly; its half-life in human studies is on the order of a few minutes. Kisspeptin-54's additional length buys it markedly longer survival, with a reported half-life around half an hour.
That difference dictated how the human research used each form. Dhillo and colleagues ran the first human study in 2005 using kisspeptin-54 infusion in healthy men and showed stimulation of the gonadotropin axis. George and colleagues showed in 2011 that kisspeptin-10 potently stimulated luteinising hormone secretion and increased pulse frequency in men. Short fragment, sharp probe; long fragment, sustained signal. The physiology is the same in both cases, but the experimental questions each form suits are different.
The most striking application used the long form. Jayasena, Dhillo and colleagues reported in 2014 that a single kisspeptin-54 injection could trigger final egg maturation in women undergoing IVF, an approach studied since as an alternative trigger with a potentially lower risk of ovarian hyperstimulation syndrome. Trials of that kind are why kisspeptin has a stronger human evidence base than most research peptides: the compound has been given to healthy volunteers and patients in controlled academic studies for two decades.
One more wrinkle: desensitisation
A system driven by pulses can be turned down by continuous stimulation, and the kisspeptin axis is no exception. Sustained high-dose kisspeptin exposure desensitises the response, an effect documented in both animal and human work. This cuts across both fragments but interacts with their kinetics: a long-lived agonist approaches continuous exposure more easily than a short-lived one. Any research design around kisspeptin has to decide whether it is studying stimulation or the taming of it, and the fragment choice follows from that.
Which one research supplies
The research market has settled largely on the short form, because a ten-residue peptide is simple to synthesise to high purity and the shared active core means receptor pharmacology carries over. That is the form our Kisspeptin-10 vial supplies, verified by certificate of analysis per batch. Published protocols using kisspeptin-54, including the IVF trigger work, used the long form specifically for its kinetics, and results from one form should be mapped onto the other with the half-life difference firmly in mind.
The takeaway
Kisspeptin-10 and kisspeptin-54 share their gene, their receptor and their active core; the fragment length changes clearance, and clearance changes what each is used to ask. The short form is the precise, fast probe most in vitro and pulse-timing work uses. The long form is the sustained signal the landmark reproductive studies used. Neither is the stronger kisspeptin. They are the same message with two different envelope sizes.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Kotani, M., Detheux, M., Vandenbogaerde, A., et al. (2001). The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry, 276(37), 34631-34636.
2. Dhillo, W. S., Chaudhri, O. B., Patterson, M., et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology and Metabolism, 90(12), 6609-6615.
3. George, J. T., Veldhuis, J. D., Roseweir, A. K., et al. (2011). Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. Journal of Clinical Endocrinology and Metabolism, 96(8), E1228-E1236.
4. Jayasena, C. N., Abbara, A., Comninos, A. N., et al. (2014). Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. Journal of Clinical Investigation, 124(8), 3667-3677.
